Procalcitonin-guided diagnosis and antibiotic stewardship revisited

被引:0
作者
Ramon Sager
Alexander Kutz
Beat Mueller
Philipp Schuetz
机构
[1] Kantonsspital Aarau,University Department of Medicine
[2] Faculty of Medicine,undefined
[3] University of Basel,undefined
来源
BMC Medicine | / 15卷
关键词
Procalcitonin; Pneumonia; Respiratory tract infection; Sepsis; Antibiotic stewardship;
D O I
暂无
中图分类号
学科分类号
摘要
Several controlled clinical studies have evaluated the potential of the infection biomarker procalcitonin (PCT) to improve the diagnostic work-up of patients with bacterial infections and its influence on decisions regarding antibiotic therapy. Most research has focused on lower respiratory tract infections and critically ill sepsis patients. A clinical utility for PCT has also been found for patients with urinary tract infections, postoperative infections, meningitis, and patients with acute heart failure with possible superinfection (i.e., pneumonia). In these indications, PCT levels measured on hospital admission were found to substantially reduce the initiation of antibiotic treatment in low-risk situations (i.e., bronchitis, chronic obstructive pulmonary disease exacerbation). For more severe infections (i.e., pneumonia, sepsis), antibiotic stewardship by monitoring of PCT kinetics resulted in shorter antibiotic treatment durations with early cessation of therapy. Importantly, these strategies appear to be safe without increasing the risk for mortality, recurrent infections, or treatment failures. PCT kinetics also proved to have prognostic value correlating with disease severity (i.e., pancreatitis, abdominal infection) and resolution of illness (i.e., sepsis). Although promising findings have been published in these different types of infections, there are a number of limitations regarding PCT, including suboptimal sensitivity and/or specificity, which makes a careful interpretation of PCT in the clinical context mandatory. This narrative review aims to update clinicians on the strengths and limitations of PCT for patient management, focusing on research conducted within the last 4 years.
引用
收藏
相关论文
共 687 条
[1]  
Mitsuma SF(2013)Promising new assays and technologies for the diagnosis and management of infectious diseases Clin Infectious Dis 56 996-1002
[2]  
Mansour MK(2011)Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future BMC Med 9 107-1628
[3]  
Dekker JP(2014)Community-acquired pneumonia New Engl J Med 371 1619-662
[4]  
Kim J(2009)Clinical predictors for BMC Pulm Med 9 4-1066
[5]  
Rahman MZ(2014) in patients presenting with community-acquired pneumonia to the emergency department Am J Med 127 1010-1331
[6]  
Tweed-Kent A(2012)Ruling out Cochrane Database Syst Rev 9 651-718
[7]  
Schuetz P(2012) in community-acquired pneumonia Clin Infect Dis 55 1059-E59
[8]  
Schuetz P(2009)Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections JAMA 302 1322-1389
[9]  
Albrich W(2011)Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis Arch Inter Med 171 717-584
[10]  
Mueller B(2013)Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial JAMA 309 E1-1418